These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 39380101)
1. Monocyte subsets in breast cancer patients under treatment with aromatase inhibitor and mucin-1 cancer vaccine. Knöbl V; Maier L; Grasl S; Kratzer C; Winkler F; Eder V; Hayden H; Sahagun Cortez MA; Sachet M; Oehler R; Frantal S; Fesl C; Zehetner K; Pfeiler G; Bartsch R; Fitzal F; Singer CF; Filipits M; Gnant M; Brostjan C J Transl Med; 2024 Oct; 22(1):913. PubMed ID: 39380101 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomised, neoadjuvant phase II study (ABCSG 34). Singer CF; Pfeiler G; Hubalek M; Bartsch R; Stöger H; Pichler A; Petru E; Bjelic-Radisic V; Greil R; Rudas M; Maria Tea MK; Wette V; Petzer AL; Sevelda P; Egle D; Dubsky PC; Filipits M; Fitzal F; Exner R; Jakesz R; Balic M; Tinchon C; Bago-Horvath Z; Frantal S; Gnant M; Eur J Cancer; 2020 Jun; 132():43-52. PubMed ID: 32325419 [TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant endocrine therapy expands stromal populations that predict poor prognosis in estrogen receptor-positive breast cancer. Brechbuhl HM; Xie M; Kopin EG; Han AL; Vinod-Paul K; Hagen J; Edgerton S; Owens P; Sams S; Elias A; Sartorius CA; Tan AC; Kabos P Mol Carcinog; 2022 Mar; 61(3):359-371. PubMed ID: 34856027 [TBL] [Abstract][Full Text] [Related]
4. p53 accumulation is a strong predictor of recurrence in estrogen receptor-positive breast cancer patients treated with aromatase inhibitors. Yamamoto M; Hosoda M; Nakano K; Jia S; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H Cancer Sci; 2014 Jan; 105(1):81-8. PubMed ID: 24118529 [TBL] [Abstract][Full Text] [Related]
5. Molecular profiling of aromatase inhibitor-treated postmenopausal breast tumors identifies immune-related correlates of resistance. Dunbier AK; Ghazoui Z; Anderson H; Salter J; Nerurkar A; Osin P; A'hern R; Miller WR; Smith IE; Dowsett M Clin Cancer Res; 2013 May; 19(10):2775-86. PubMed ID: 23493347 [TBL] [Abstract][Full Text] [Related]
6. Oestrogen deprivation induces chemokine production and immune cell recruitment in in vitro and in vivo models of oestrogen receptor-positive breast cancer. Hazlett J; Niemi V; Aiderus A; Powell K; Wise L; Kemp R; Dunbier AK Breast Cancer Res; 2021 Oct; 23(1):95. PubMed ID: 34602068 [TBL] [Abstract][Full Text] [Related]
7. In situ aromatase expression in primary tumor is associated with estrogen receptor expression but is not predictive of response to endocrine therapy in advanced breast cancer. Lykkesfeldt AE; Henriksen KL; Rasmussen BB; Sasano H; Evans DB; Møller S; Ejlertsen B; Mouridsen HT BMC Cancer; 2009 Jun; 9():185. PubMed ID: 19531212 [TBL] [Abstract][Full Text] [Related]
8. CYR61 Confers the Sensitivity to Aromatase Inhibitor Letrozole in ER Positive Breast Carcinoma. Jia X; Liu G; Cheng J; Shen Z; Shao Z Curr Cancer Drug Targets; 2017; 17(2):191-197. PubMed ID: 27113745 [TBL] [Abstract][Full Text] [Related]
9. Peripheral Blood Classical Monocytes and Plasma Interleukin 10 Are Associated to Neoadjuvant Chemotherapy Response in Breast Cancer Patients. Valdés-Ferrada J; Muñoz-Durango N; Pérez-Sepulveda A; Muñiz S; Coronado-Arrázola I; Acevedo F; Soto JA; Bueno SM; Sánchez C; Kalergis AM Front Immunol; 2020; 11():1413. PubMed ID: 32733470 [TBL] [Abstract][Full Text] [Related]
10. Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer. Weigel MT; Ghazoui Z; Dunbier A; Pancholi S; Dowsett M; Martin LA Breast Cancer Res; 2012 May; 14(3):R78. PubMed ID: 22608253 [TBL] [Abstract][Full Text] [Related]
11. High estrogen receptor expression and low Ki67 expression are associated with improved time to progression during first-line endocrine therapy with aromatase inhibitors in breast cancer. Endo Y; Toyama T; Takahashi S; Sugiura H; Yoshimoto N; Iwasa M; Kobayashi S; Fujii Y; Yamashita H Int J Clin Oncol; 2011 Oct; 16(5):512-8. PubMed ID: 21431343 [TBL] [Abstract][Full Text] [Related]
12. Aromatase inhibitors increase the sensitivity of human tumor cells to monocyte-mediated, antibody-dependent cellular cytotoxicity. Braun DP; Crist KA; Shaheen F; Staren ED; Andrews S; Parker J Am J Surg; 2005 Oct; 190(4):570-1. PubMed ID: 16164922 [TBL] [Abstract][Full Text] [Related]
13. GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors. Morandi A; Martin LA; Gao Q; Pancholi S; Mackay A; Robertson D; Zvelebil M; Dowsett M; Plaza-Menacho I; Isacke CM Cancer Res; 2013 Jun; 73(12):3783-95. PubMed ID: 23650283 [TBL] [Abstract][Full Text] [Related]
14. Targeting the receptor tyrosine kinase RET in combination with aromatase inhibitors in ER positive breast cancer xenografts. Andreucci E; Francica P; Fearns A; Martin LA; Chiarugi P; Isacke CM; Morandi A Oncotarget; 2016 Dec; 7(49):80543-80553. PubMed ID: 27602955 [TBL] [Abstract][Full Text] [Related]
15. Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer: results from the Breast International Group Trial 1-98. Kensler KH; Regan MM; Heng YJ; Baker GM; Pyle ME; Schnitt SJ; Hazra A; Kammler R; Thürlimann B; Colleoni M; Viale G; Brown M; Tamimi RM Breast Cancer Res; 2019 Feb; 21(1):30. PubMed ID: 30795773 [TBL] [Abstract][Full Text] [Related]
17. Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance). Ellis MJ; Suman VJ; Hoog J; Goncalves R; Sanati S; Creighton CJ; DeSchryver K; Crouch E; Brink A; Watson M; Luo J; Tao Y; Barnes M; Dowsett M; Budd GT; Winer E; Silverman P; Esserman L; Carey L; Ma CX; Unzeitig G; Pluard T; Whitworth P; Babiera G; Guenther JM; Dayao Z; Ota D; Leitch M; Olson JA; Allred DC; Hunt K J Clin Oncol; 2017 Apr; 35(10):1061-1069. PubMed ID: 28045625 [TBL] [Abstract][Full Text] [Related]
18. Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: A Secondary Analysis of the BIG 1-98 Randomized Clinical Trial. Luen SJ; Asher R; Lee CK; Savas P; Kammler R; Dell'Orto P; Biasi OM; Demanse D; JeBailey L; Dolan S; Hackl W; Thuerlimann B; Viale G; Colleoni M; Regan MM; Loi S JAMA Oncol; 2018 Oct; 4(10):1335-1343. PubMed ID: 29902286 [TBL] [Abstract][Full Text] [Related]
20. Impact of combining the progesterone receptor and preoperative endocrine prognostic index (PEPI) as a prognostic factor after neoadjuvant endocrine therapy using aromatase inhibitors in postmenopausal ER positive and HER2 negative breast cancer. Kurozumi S; Matsumoto H; Inoue K; Tozuka K; Hayashi Y; Kurosumi M; Oyama T; Fujii T; Horiguchi J; Kuwano H PLoS One; 2018; 13(8):e0201846. PubMed ID: 30080878 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]